MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

What Was Tested

The trial (phase 2) is built around Semaglutide.

It had two arms (groups): Arm 1: ECC4703 + semaglutide (experimental) and Arm 2: Placebo + semaglutide (placebo comparator).

ECC4703 orally QD + semaglutide SC once weekly.

Placebo orally QD + semaglutide SC once weekly.

The registry classes the interventions as drug.

Who Took Part

The registry lists 151 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Capable of providing written informed consent and complying with all trial procedures. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential). Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening.

The full record lists 6 inclusion and 15 exclusion criteria; among the exclusions: history or current diagnosis of type 1 or type 2 diabetes mellitus; obesity induced by endocrine disorders such as cushing's syndrome or monogenic or syndromic obesity such as prader-willi syndrome; use of glp-1 agonist treatment within the last 6 months prior to screening.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2026-03-23 with completion listed for 2026-10-15.

It ran at 15 sites in United States (15).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage Change in Body Weight from Baseline (Week 9) to Week 20 (time frame: Baseline (Week 9) to Week 20). Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis (time frame: Baseline (Week 9) to Week 20). Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis (time frame: Baseline (Week 9) to Week 20).

It also tracked 17 secondary outcomes, for example Change in Percentage Lean Mass as Measured by DXA, Change in Percentage Total Body Fat Mass as Measured by DXA, Change in Percentage Visceral Fat Mass as Measured by DXA, Change in Glycemic Parameters from Baseline (Week 9) to Week 20, Change in Lipid Parameters from Baseline (Week 9) to Week 20 and Change in Body Weight (kg) from Baseline (Week 9) to Week 20.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 151 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.